AstraZeneca’s Phase III FLAURA2 trial shows positive result
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
Biocon Foundation is also expanding its reach with this first initiative in Channapatna region
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
CRISPR-based detection enables highly specific molecular recognition
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Subscribe To Our Newsletter & Stay Updated